title: Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
abstract: We identified 103 consecutive patients who, 5 years after allogeneic transplantation for chronic myeloid leukaemia (CML), were in molecular remission (MR). The 103 patients were divided into three groups on the basis of reverse transcription-polymerase chain reaction (RT-PCR) studies for BCR-ABL transcripts in the first 5 years post transplant: Group A comprised 63 patients who had been continuously PCR negative; Group B comprised 20 patients with one or more positive PCR result but only at a low level; and Group C comprised 20 patients who had fulfilled the criteria for molecular relapse, been treated with donor lymphocyte infusions (DLI) and had thereafter regained complete MR within the 5-year post-transplant period. The median follow-up for all 103 patients was 8.4 years from transplant (range 5-17.6 years). In group A only one patient relapsed at 9.2 years. In group B eight patients (40%) relapsed: six at molecular, one at cytogenetic and one haematological levels. The actuarial probabilities of survival at 10 years for patients in Groups A, B and C were 97.4%, 92.9% and 100% respectively; the probabilities of relapse were 3%, 54% and 0% respectively. We conclude that molecular studies during the first 5 years post transplant can help to predict long-term leukaemia-free survival and, possibly, cure of CML.
authors.affiliation: Department of Haematology, Hammersmith Hospital, Imperial College School of Medicine, London, UK.
authors.forename: T I
authors.initials: TI
authors.lastname: Mughal
authors.forename: A
authors.initials: A
authors.lastname: Yong
authors.forename: R M
authors.initials: RM
authors.lastname: Szydlo
authors.forename: F
authors.initials: F
authors.lastname: Dazzi
authors.forename: E
authors.initials: E
authors.lastname: Olavarria
authors.forename: F
authors.initials: F
authors.lastname: van Rhee
authors.forename: J
authors.initials: J
authors.lastname: Kaeda
authors.forename: N C
authors.initials: NC
authors.lastname: Cross
authors.forename: C
authors.initials: C
authors.lastname: Craddock
authors.forename: E
authors.initials: E
authors.lastname: Kanfer
authors.forename: J
authors.initials: J
authors.lastname: Apperley
authors.forename: J M
authors.initials: JM
authors.lastname: Goldman
mesh_terms: D000293:Adolescent; D000328:Adult; D001804:Blood Transfusion, Autologous; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D005819:Genetic Markers; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D005819:Genetic Markers; D016044:Fusion Proteins, bcr-abl